documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
43 rows where docket_id = "FDA-2007-D-0369" and posted_year = 2020 sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: last_modified, posted_date (date)
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2007-D-0369-0529 | FDA | None FDA-2007-D-0369 | PSG_203858 - Draft Guidance on Lomitapide Mesylate | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:16Z | 0 | 0 | 0900006484968cb1 | |||
| FDA-2007-D-0369-0522 | FDA | None FDA-2007-D-0369 | PSG_022563 - Draft Guidance on Calcipotriene | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:14Z | 0 | 0 | 0900006484968caa | |||
| FDA-2007-D-0369-0526 | FDA | None FDA-2007-D-0369 | PSG_200063 - Draft Guidance on Bupropion Hydrochloride; Naltrexone Hydrochloride | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:15Z | 0 | 0 | 0900006484968cae | |||
| FDA-2007-D-0369-0513 | FDA | None FDA-2007-D-0369 | PSG_011751 - Draft Guidance on Fluphenazine Hydrochloride | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:11Z | 0 | 0 | 0900006484968d7b | |||
| FDA-2007-D-0369-0525 | FDA | None FDA-2007-D-0369 | PSG_061904 - Draft Guidance on Erythromycin Ethylsuccinate | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:15Z | 0 | 0 | 0900006484968cad | |||
| FDA-2007-D-0369-0533 | FDA | None FDA-2007-D-0369 | PSG_207071 - Draft Guidance on Azelaic Acid | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:17Z | 0 | 0 | 0900006484968cb5 | |||
| FDA-2007-D-0369-0537 | FDA | None FDA-2007-D-0369 | PSG_208910 - Draft Guidance on Vancomycin Hydrochloride | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:17Z | 0 | 0 | 0900006484968cb9 | |||
| FDA-2007-D-0369-0540 | FDA | None FDA-2007-D-0369 | PSG_211635 - Draft Guidance on Diazepam | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:18Z | 0 | 0 | 0900006484968cbc | |||
| FDA-2007-D-0369-0514 | FDA | None FDA-2007-D-0369 | PSG_016418 - Draft Guidance on Propranolol Hydrochloride | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:13Z | 0 | 0 | 0900006484968d7c | |||
| FDA-2007-D-0369-0544 | FDA | None FDA-2007-D-0369 | PSG_212862 - Draft Guidance on Pretomanid | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:20Z | 0 | 0 | 0900006484968cc0 | |||
| FDA-2007-D-0369-0523 | FDA | None FDA-2007-D-0369 | PSG_050207 - Draft Guidance on Erythromycin Ethylsuccinate | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:15Z | 0 | 0 | 0900006484968cab | |||
| FDA-2007-D-0369-0531 | FDA | None FDA-2007-D-0369 | PSG_205777 - Draft Guidance on Naloxone Hydrochloride; Oxycodone Hydrochloride | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:17Z | 0 | 0 | 0900006484968cb3 | |||
| FDA-2007-D-0369-0534 | FDA | None FDA-2007-D-0369 | PSG_207318 - Draft Guidance on Pimavanserin Tartrate | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:17Z | 0 | 0 | 0900006484968cb6 | |||
| FDA-2007-D-0369-0543 | FDA | None FDA-2007-D-0369 | PSG_212161 - Draft Guidance on Tafamidis | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:18Z | 0 | 0 | 0900006484968cbf | |||
| FDA-2007-D-0369-0521 | FDA | None FDA-2007-D-0369 | PSG_022013 - Draft Guidance on Clobetasol Propionate | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:14Z | 0 | 0 | 0900006484968ca9 | |||
| FDA-2007-D-0369-0517 | FDA | None FDA-2007-D-0369 | PSG_018662 - Draft Guidance on Isotretinoin | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:14Z | 0 | 0 | 0900006484968ca5 | |||
| FDA-2007-D-0369-0541 | FDA | None FDA-2007-D-0369 | PSG_211672 - Draft Guidance on Lefamulin Acetate | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:18Z | 0 | 0 | 0900006484968cbd | |||
| FDA-2007-D-0369-0530 | FDA | None FDA-2007-D-0369 | PSG_205613 - Draft Guidance on Budesonide | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:16Z | 0 | 0 | 0900006484968cb2 | |||
| FDA-2007-D-0369-0518 | FDA | None FDA-2007-D-0369 | PSG_021438 - Draft Guidance on Propranolol Hydrochloride | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:14Z | 0 | 0 | 0900006484968ca6 | |||
| FDA-2007-D-0369-0520 | FDA | None FDA-2007-D-0369 | PSG_021978 - Draft Guidance on Desonide | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:14Z | 0 | 0 | 0900006484968ca8 | |||
| FDA-2007-D-0369-0510 | FDA | None FDA-2007-D-0369 | Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Notice | Notice of Availability | 2020-11-19T05:00:00Z | 2020 | 11 | 2020-11-19T05:00:00Z | 2021-01-20T04:59:59Z | 2020-11-19T14:06:28Z | 2020-25602 | 0 | 0 | 09000064849686e1 |
| FDA-2007-D-0369-0519 | FDA | None FDA-2007-D-0369 | PSG_021951 - Draft Guidance on Isotretinoin | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:14Z | 0 | 0 | 0900006484968ca7 | |||
| FDA-2007-D-0369-0539 | FDA | None FDA-2007-D-0369 | PSG_211225 - Draft Guidance on Ceritinib | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:18Z | 0 | 0 | 0900006484968cbb | |||
| FDA-2007-D-0369-0538 | FDA | None FDA-2007-D-0369 | PSG_210833 - Draft Guidance on Clobazam | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:18Z | 0 | 0 | 0900006484968cba | |||
| FDA-2007-D-0369-0511 | FDA | None FDA-2007-D-0369 | PSG_008720 - Draft Guidance on Levorphanol Tartrate | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:11Z | 0 | 0 | 0900006484968d79 | |||
| FDA-2007-D-0369-0524 | FDA | None FDA-2007-D-0369 | PSG_050529 - Draft Guidance on Erythromycin Ethylsuccinate; Sulfisoxazole Acetyl | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:15Z | 0 | 0 | 0900006484968cac | |||
| FDA-2007-D-0369-0535 | FDA | None FDA-2007-D-0369 | PSG_207960 - Draft Guidance on Methylphenidate Hydrochloride | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:17Z | 0 | 0 | 0900006484968cb7 | |||
| FDA-2007-D-0369-0542 | FDA | None FDA-2007-D-0369 | PSG_211996 - Draft Guidance on Tafamidis Meglumine | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:18Z | 0 | 0 | 0900006484968cbe | |||
| FDA-2007-D-0369-0516 | FDA | None FDA-2007-D-0369 | PSG_018553 - Draft Guidance on Propranolol Hydrochloride | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:13Z | 0 | 0 | 0900006484968d7e | |||
| FDA-2007-D-0369-0527 | FDA | None FDA-2007-D-0369 | PSG_200655 - Draft Guidance on Fluorodopa F-18 | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:15Z | 0 | 0 | 0900006484968caf | |||
| FDA-2007-D-0369-0512 | FDA | None FDA-2007-D-0369 | PSG_010571 - Draft Guidance on Prochlorperazine Maleate | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:11Z | 0 | 0 | 0900006484968d7a | |||
| FDA-2007-D-0369-0528 | FDA | None FDA-2007-D-0369 | PSG_202292 - Draft Guidance on Crofelemer | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:15Z | 0 | 0 | 0900006484968cb0 | |||
| FDA-2007-D-0369-0532 | FDA | None FDA-2007-D-0369 | PSG_205920 - Draft Guidance on Epinephrine | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:17Z | 0 | 0 | 0900006484968cb4 | |||
| FDA-2007-D-0369-0536 | FDA | None FDA-2007-D-0369 | PSG_208246 - Draft Guidance on Tofacitinib Citrate | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:17Z | 0 | 0 | 0900006484968cb8 | |||
| FDA-2007-D-0369-0515 | FDA | None FDA-2007-D-0369 | PSG_017351 - Draft Guidance on Hydrocortisone Acetate | Supporting & Related Material | Guidance | 2020-11-19T05:00:00Z | 2020 | 11 | 2024-11-06T23:41:13Z | 0 | 0 | 0900006484968d7d | |||
| FDA-2007-D-0369-0508 | FDA | None FDA-2007-D-0369 | Product-Specific Guidance for Tiotropium Bromide; Draft Guidance for Industry; Availability | Notice | Notice of Availability | 2020-11-18T05:00:00Z | 2020 | 11 | 2020-11-18T05:00:00Z | 2021-01-20T04:59:59Z | 2021-01-16T02:01:08Z | 2020-25412 | 0 | 0 | 09000064849661a3 |
| FDA-2007-D-0369-0509 | FDA | None FDA-2007-D-0369 | Draft Guidance on Tiotropium Bromide | Other | Guidance | 2020-11-18T05:00:00Z | 2020 | 11 | 2020-11-18T05:00:00Z | 2024-11-06T23:40:25Z | 1 | 0 | 0900006484965ca1 | ||
| FDA-2007-D-0369-0502 | FDA | None FDA-2007-D-0369 | Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Notice | Notice of Availability | 2020-08-31T04:00:00Z | 2020 | 8 | 2020-08-31T04:00:00Z | 2020-10-31T03:59:59Z | 2020-10-24T01:00:52Z | 2020-19164 | 0 | 0 | 090000648482cf4b |
| FDA-2007-D-0369-0498 | FDA | None FDA-2007-D-0369 | Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Notice | Notice of Availability | 2020-06-04T04:00:00Z | 2020 | 6 | 2020-06-04T04:00:00Z | 2020-08-04T03:59:59Z | 2020-08-04T01:01:45Z | 2020-12100 | 0 | 0 | 09000064846c9e54 |
| FDA-2007-D-0369-0493 | FDA | None FDA-2007-D-0369 | Product-Specific Guidances; Guidance for Industry; Availability | Notice | Notice of Availability | 2020-04-14T04:00:00Z | 2020 | 4 | 2020-04-14T04:00:00Z | 2024-11-06T23:33:20Z | 2020-07751 | 1 | 0 | 09000064844a2653 | |
| FDA-2007-D-0369-0484 | FDA | None FDA-2007-D-0369 | Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Notice | Notice of Availability | 2020-03-03T05:00:00Z | 2020 | 3 | 2020-03-03T05:00:00Z | 2020-05-05T03:59:59Z | 2020-04-24T01:01:24Z | 2020-04320 | 0 | 0 | 09000064843d883c |
| FDA-2007-D-0369-0482 | FDA | None FDA-2007-D-0369 | Draft Guidance on Levonorgestrel | Other | Guidance | 2020-01-23T05:00:00Z | 2020 | 1 | 2020-01-23T05:00:00Z | 2020-03-24T03:59:59Z | 2024-11-12T23:15:48Z | 1 | 0 | 09000064842dfec7 | |
| FDA-2007-D-0369-0481 | FDA | None FDA-2007-D-0369 | Product-Specific Guidance for Levonorgestrel; Intrauterine Device; Revised Draft Guidance for Industry; Availability | Notice | Notice of Availability | 2020-01-23T05:00:00Z | 2020 | 1 | 2020-01-23T05:00:00Z | 2020-03-24T03:59:59Z | 2020-04-09T17:01:46Z | 2020-01072 | 0 | 0 | 09000064842de6de |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;